MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 Subjects
- First Online:
- Cite this article as:
- Mao, C., Qiu, LX., Zhan, P. et al. J Cancer Res Clin Oncol (2010) 136: 975. doi:10.1007/s00432-009-0742-x
Published data on the association between manganese superoxide dismutase (MnSOD) Val16Ala polymorphism and prostate cancer (PCA) risk are inconclusive. To derive a more precise estimate of the association between them, a meta-analysis was performed.
PubMed and Embase were searched. All eligible studies were retrieved. The pooled odds ratio (OR) with 95% confidence interval (CI) for PCA risk associated with Val/Ala versus Val/Val, Ala/Ala versus Val/Val, dominant model (Ala/Ala + Val/Ala vs. Val/Val), and recessive model (Ala/Ala vs. Val/Ala + Val/Val) were estimated, respectively.
A total of 12 studies including 8,962 subjects were involved in this meta-analysis. Overall, the meta-analysis indicated that significantly elevated cancer risk was associated with Ala variant genotype when all the eligible studies were pooled into the meta-analysis (for Val/Ala vs. Val/Val: OR = 1.11, 95% CI = 1.00–1.24; for Ala/Ala vs. Val/Val: OR = 1.22, 95% CI = 1.00–1.49; for dominant model: OR = 1.14, 95% CI = 1.03–1.26). In the subgroup analysis by ethnicity, statistically significant increased risks were found among Caucasians with Ala allele (for Val/Ala vs. Val/Val: OR = 1.12, 95% CI = 1.00–1.25; for dominant model: OR = 1.14, 95% CI = 1.02–1.26). However, no significant associations were found in Africans.
This meta-analysis suggests that the Ala allele of the MnSOD gene was a low-penetrance susceptible gene in PCA development, especially in Caucasians.